Skip to main content

May 2020

 

Clinical courses

 

Clinical research courses

Require Associate in Development Regulatory Centers at Novartis

Novartis has one of the most exciting product pipelines in the industry today. A pipeline of innovative medicines brought to life by diverse, talented and performance driven people. All of which makes them one of the most rewarding employers in their field.

Post : Associate, DRC (Development Regulatory Centers)

REVIEW ON COVID -19(CORONA VIRUS DISEASE)

AUTHORS :
*Tinku Kumar Singh1, Satish Kumar1, Purna Tiwari2
1 Indchemie health Specialities Pvt. Ltd
2 Alkem health science Ltd
tinku20190@gmail.com

 

ABSTRACT : The World Health Organization (WHO) has declared the corona virus disease 2019 (COVID-19) a pandemic. In January 2020, a previously unknown new virus was identified subsequently named the 2019 novel corona virus, and samples obtained from cases and analysis of the virus’ genetics indicated that this was the cause of the outbreak. Corona viruses are a group of related viruses that cause diseases in mammals and birds. The COVID-19 virus spreads primarily through droplets of saliva or discharge from the nose when an infected person coughs or sneezes. Corona viruses are large pleomorphic spherical particles with bulbous surface projections. Isolation remains the most effective measure for containment of COVID-19. Moreover unnecessary administration of antibiotics should also be avoided. Critically ill patients require high flow oxygen, extracorporeal membrane oxygenation (ECMO), glucocorticoid therapy, and convalescent plasma. Therapeutically, aerosol administration of alpha-interferon (5 million units twice daily), chloroquine phosphate, and lopinavir/ritonavir have been suggested.

Scientists from Jawaharlal Nehru Centre For Advanced Scientific Research (JNCASR) an autonomous institute under the Department of Science & Technology (DST), Govt. of India have modified the structure of Berberine, a natural and cheap product similar to curcumin, available commercially, into Ber-D to use as a Alzheimer’s inhibitor. Their research work has been published in the scientific journal iSceince. Alzheimer’s disease is the most prevalent neurodegenerative disorder and accounts for more than 70% of all dementia. The multifactorial nature of the disease attributed to multifaceted toxicity has made it difficult for researchers to develop effective medication.

Hospitalized patients with advanced COVID-19 and lung involvement who received remdesivir recovered faster than similar patients who received placebo, according to a preliminary data analysis from a randomized, controlled trial involving 1063 patients, which began on February 21. The trial (known as the Adaptive COVID-19 Treatment Trial, or ACTT), sponsored by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, is the first clinical trial launched in the United States to evaluate an experimental treatment for COVID-19.

The National Institutes of Health announced a new initiative aimed at speeding innovation, development and commercialization of COVID-19 testing technologies, a pivotal component needed to return to normal during this unprecedented global pandemic. With a USD 1.5 billion investment from federal stimulus funding, the newly launched Rapid Acceleration of Diagnostics (RADx) initiative will infuse funding into early innovative technologies to speed development of rapid and widely accessible COVID-19 testing.

At the same time, NIH will seek opportunities to move more advanced diagnostic technologies swiftly through the development pipeline toward commercialization and broad availability. NIH will work closely with the U.S. Food and Drug Administration, the Centers for Disease Control and Prevention and the Biomedical Advanced Research and Development Authority (BARDA) to advance these goals.

The stimulus investment supercharges NIH’s strong research efforts already underway focused on prevention and treatment of COVID-19, including the recently announced planned Accelerating COVID-19 Therapeutic Interventions and Vaccines public-private partnership to coordinate the international research response to the pandemic.


As part of this initiative, NIH is urging all scientists and inventors with a rapid testing technology to compete in a national COVID-19 testing challenge for a share of up to USD 500 million over all phases of development. The technologies will be put through a highly competitive, rapid three-phase selection process to identify the best candidates for at-home or point-of-care tests for COVID-19.

Finalists will be matched with technical, business and manufacturing experts to increase the odds of success. If certain selected technologies are already relatively far along in development, they can be put on a separate track and be immediately advanced to the appropriate step in the commercialization process. The goal is to make millions of accurate and easy-to-use tests per week available to all Americans by the end of summer 2020, and even more in time for the flu season.


<< Back to Pharma News

Subscribe to PharmaTutor News Alerts by Email

CSIR-Central Scientific Instruments Organisation (CSIR-CSIO), Chandigarh, has designed and developed an innovative technology for effective disinfection and sanitization to fight with corona pandemic. CSIR-CSIO has transferred this technology to a Nagpur-based company, Rite Water Solutions Pvt. Ltd., for commercialization and large-scale production. This technology has been found very efficient and effective to stop the spread of coronavirus and pathogens, say CSIR-CSIO scientists.

Career for B.Pharm, M.Pharm in Materials, Production, Stores at KAPL - Government Enterprise | 14 posts

Karnataka Antibiotics & Pharmaceuticals Ltd., (KAPL) Bangalore is a Government Enterprise.  From a modest beginning in 1984, KAPL has grown from strength to strength in the areas of manufacturing and marketing of various life saving and essential drugs. With an ISO accredition from KPMG, Netherlands, KAPL is recognised for its total commitment to quality and services in domestic and international markets. On profit from inception, KAPL facilities are approved by many international clients.

Recruitment for D.Pharm, B.Pharm in Civil Hospital | 07 posts

Eligible candidates may appear in the office of Civil Surgeon, A- Block, 5th Floor, premises of Civil Hospital, Sector-06. Panchkula for the below mentioned posts under National Health Mission. Posts are purely on contractual basis for fixed contract period initially up to 30-06-2020 strictly on performance basis or subject to further administrative approval.

Post : EMT (Referral Transport Scheme)